Asset Details
Do you wish to reserve the book?
Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records
Do you wish to request the book?
Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records
2024
Overview
Background
There is limited evidence on the safety of Hormone Replacement Therapy (HRT) in women with cancer. Therefore, we systematically examined HRT use and cancer-specific mortality in women with 17 site-specific cancers.
Methods
Women newly diagnosed with 17 site-specific cancers from 1998 to 2019, were identified from general practitioner (GP) records, hospital diagnoses or cancer registries in Scotland, Wales and England. Breast cancer patients were excluded because HRT is contraindicated in breast cancer patients. The primary outcome was time to cancer-specific mortality. Time-dependent Cox regression models were used to calculate adjusted hazard ratios (HR) and 95% confidence intervals (95% CIs) for cancer-specific mortality by systemic HRT use.
Results
The combined cancer cohorts contained 182,589 women across 17 cancer sites. Overall 7% of patients used systemic HRT after their cancer diagnosis. There was no evidence that HRT users, compared with non-users, had higher cancer-specific mortality at any cancer site. In particular, no increase was observed in common cancers including lung (adjusted HR = 0.98 95% CI 0.90, 1.07), colorectal (adjusted HR = 0.79 95% CI 0.70, 0.90), and melanoma (adjusted HR = 0.77 95% CI 0.58, 1.02).
Conclusions
We observed no evidence of increased cancer-specific mortality in women with a range of cancers (excluding breast) receiving HRT.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
